Courtney Flaherty

DK210 (EGFR) showed evidence of wild-type IL-2 signaling, CRS mitigation, and immune response signaling in patients with solid tumors.

Updated interim data show high complete responses and tolerability with padeliporfin VTP in low-grade upper tract urothelial cancer.

Angela Hirbe, MD, PhD, discusses the potential significance of MEK inhibitors such as mirdametinib for adult and pediatric patients with NF1-PN.

Ruxolitinib plus low-dose pegylated interferon alfa-2a is well tolerated and efficacious in patients with newly diagnosed polycythemia vera.

David S. Miller, MD, discusses key efficacy, safety, and quality-adjusted survival data with selinexor in TP53 wild-type endometrial cancer.

Marc J. Braunstein, MD, PhD, discusses the diagnosis, prevention, and treatment of patients with veno-occlusive disease post-transplant.

Domenica Lorusso, MD, PhD, and Premal Thaker, MD, highlight the upcoming phase 3 ROSELLA trial of relacorilant in platinum-resistant ovarian cancer.

First-line sugemalimab plus chemotherapy has received UK approval for metastatic NSCLC without EGFR-sensitizing mutations or ALK/ROS1/RET alterations.

Daniel DeAngelo MD, PhD, discusses the evolution of management strategies and treatment goals across several hematologic malignancies.

IDE397 is the first MAT2A inhibitor to show clinical activity and safety in patients with MTAP-deletion urothelial cancer and non–small cell lung cancer.

Nataliya Uboha, MD, PhD, discusses the FDA’s ODAC’s recommendation to restrict anti–PD-1 agents to patients with PD-L1–positive ESCC.

Daniel DeAngelo MD, PhD, discusses the incorporation of JAK inhibitors into the myelofibrosis treatment paradigm.

HC-7366 has received FDA fast track designation for the treatment of adult patients with relapsed/refractory acute myeloid leukemia.

Cabozantinib plus atezolizumab did not produce superior OS outcomes vs a second novel hormonal therapy in metastatic castration-resistant prostate cancer.

Ashraf Z. Badros, MBCHB, discusses the use of daratumumab plus lenalidomide as maintenance therapy after transplant in newly diagnosed multiple myeloma.

Screening for donor-derived clonal hematopoiesis may have prognostic value for outcomes following auto-HSCT in patients with hematologic malignancies.

Adding savolitinib to osimertinib produced clinically meaningful responses in EGFR-mutant, MET-overexpressed NSCLC following progression on osimertinib.

Joseph M. Scandura, MD, PhD, discusses the importance of research with single-agent selinexor in JAK inhibitor–naive myelofibrosis.

China’s CDE has granted breakthrough therapy designation to first-line sunvozertinib for EGFR exon 20 insertion mutation–positive NSCLC.

A single-dose formulation of paclitaxel for injectable suspension has been launched in the United States for metastatic breast cancer.

LMP744 has been granted orphan drug designation by the FDA for the treatment of patients with glioma.

A next generation sequencing–based companion diagnostic has received marketing approval in China for sunvozertinib in EGFR exon 20–positive NSCLC.

Complete responses were achieved by 2 patients with advanced CD123-positive hematologic malignancies who received VIP943 in a phase 1 study.

Elias Jabbour, MD, discusses how advancements in the administration and sequencing of TKIs have improved long-term prognosis for patients with CML.

Saad Z. Usmani, MD, MBA, FACP, FASCO, expands on data from the CEPHEUS trial of D-VRd in transplant-ineligible/-deferred, newly diagnosed multiple myeloma.

Isabel Preeshagul, DO, MBS, discusses ongoing efforts to expand treatment options for patients with extensive- or limited-stage small cell lung cancer.

Illuccix has been approved in Canada for the selection of patients with mCRPC eligible for treatment with PSMA1-targeted radionuclide therapy.

Isabel Preeshagul, DO, MBS, discusses considerations for treatment selection in the first and second line for patients with EGFR-mutated NSCLC.

Jared Weiss, MD, discusses survival benefits seen with the therapeutic cancer vaccine Versamune HPV plus first-line pembrolizumab in HPV16-positive HNSCC.

No significant differences in patient-reported outcomes were observed with BPd vs PVd among patients with relapsed/refractory multiple myeloma.